I don't have the specifics of that case, but there were some drug shortages in some epileptic drugs, and that's probably what the situation was there, which is a significant problem for a number of drug classes, particularly some generic drug classes where there might only be one manufacturer and that manufacturer has had problems with its supply of the chemicals that might come from other countries around the world. It's a delicate situation for that patient in that we now have to find a therapeutic alternative. That's where to provide the best care the physicians need to look at all the potential products available for that child. Hopefully there is an alternate that will provide some benefit to her.
On April 13th, 2016. See this statement in context.